Role of muscarinic receptors in the activation of the ventral subiculum and the consequences for dopamine release in the nucleus accumbens

European Journal of Pharmacology

Volumn 460, Issue 2-3, 2003, Pages 117-125

  Moss, Sarah ^a   Sharott, Andrew ^a   Goodhead, Lucy H ^a   Mitchell, Stephen N ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

(Rat); Dopamine; Microdialysis; Muscarinic receptor; Nucleus accumbens; Ventral subiculum

Indexed keywords

4 AMINOBUTYRIC ACID; ATROPINE; BICUCULLINE; CARBACHOL; DOPAMINE; EXO 6 BUTYLTHIO 1,2,5 THIADIZOL 3 YL 1 AZABICYCLO[3.2.1]OCTANE; METHOCTRAMINE; MUSCARINIC M1 RECEPTOR AGONIST; MUSCARINIC M2 RECEPTOR AGONIST; MUSCARINIC M2 RECEPTOR ANTAGONIST; MUSCARINIC M4 RECEPTOR; MUSCARINIC RECEPTOR; NICOTINIC AGENT; OXOTREMORINE; PILOCARPINE; SPIRO[1 AZABICYCLO[2.2.2]OCTANE 3,2' THIAZOLIDINE] 2' ONE; SPIRO[1 AZABICYCLO[2.2.2]OCTANE 3,5' OXAZOLIDINE] 2' ONE; UNCLASSIFIED DRUG; XANOMELINE;

ANESTHESIA; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOPAMINE RELEASE; DRUG EFFECT; MALE; NEUROTRANSMISSION; NONHUMAN; NUCLEUS ACCUMBENS; PRIORITY JOURNAL; PROTEIN FUNCTION; RAT;

ANIMALS; ATROPINE; BICUCULLINE; BRIDGED COMPOUNDS; CARBACHOL; CHOLINERGIC AGONISTS; DIAMINES; DOPAMINE; HIPPOCAMPUS; MALE; MICRODIALYSIS; MUSCARINIC AGONISTS; MUSCARINIC ANTAGONISTS; NICOTINE; NUCLEUS ACCUMBENS; OXOTREMORINE; PILOCARPINE; PYRIDINES; RATS; RECEPTORS, MUSCARINIC; SPIRO COMPOUNDS; THIADIAZOLES; TROPANES;

EID: 0037462478     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(02)02948-5     Document Type: Article

References (42)

1. Bernard V., Normand E., Bloch B. Phenotypical characterization of the rat striatal neurons expressing muscarinic receptor genes. J. Neurosci. 12:1992;3591-3600.
2. Blaha C.D., Yang C.R., Floresco S.B., Barr A.M., Phillips A.G. Stimulation of the ventral subiculum of the hippocampus evokes glutamate-mediated changes in dopamine efflux in the rat nucleus accumbens. Eur. J. Neurosci. 9:1997;902-911.
3. Brenner D.M., Bardgett M.E. Haloperidol blocks increased locomotor activity elicited by carbachol infusion into the ventral hippocampal formation. Pharmacol. Biochem. Behav. 60:1998;759-764.
4. Brudzynski S.M., Gibson C.J. Release of dopamine in the nucleus accumbens caused by stimulation of the subiculum in freely moving rats. Brain Res. Bull. 42:1997;303-308.
5. 1 muscarinic agonist xanomeline (LY2466708/NNC11-0232). J. Pharmacol. Exp. Ther. 269:1994;282-289.
6. Bymaster F.P., Whitesitt C.A., Shannon H.E., DeLapp N.W., Ward J.S., Calligaro D.O., Shipley L.A., Buelke-Sam J.L., Bodick N.C., Farde L., Sheardown M.J., Olesen P.H., Hansen K.T., Suzdak P.D., Swerdberg M.D.B., Sauerberg P., Mitch C.H. Xanomeline: a selective muscarinic agonist for the treatment of Alzheimer's Disease. Drug Dev. Res. 40:1997;158-170.
7. Caulfield M.P. Muscarinic receptors: characterisation, coupling and function. Pharmacol. Ther. 58:1993;319-379.
8. 3H]GABA. Neuroscience. 22:1987;425-439.
9. DeFrance J.F., Marchand J.E., Stanley J.C., Sikes R.W., Chronister R.B. Convergence of excitatory amygdaloid and hippocampal input in the nucleus accumbens septi. Brain Res. 185:1980;183-186.
10. Dörje F., Wess J., Lambrecht G., Tacke R., Mutschler E., Brann M.R. Antagonist binding profiles of five cloned human muscarinic receptor subtypes. J. Pharmacol. Exp. Ther. 256:1991;727-733.
11. Floresco S.B., Todd C.L., Grace A.A. Glutamatergic afferents from the hippocampus to the nucleus accumbens regulate activity of ventral tegmental area dopamine neurons. J. Neurosci. 21:2001;4915-4922.
12. Fuller T.A., Russchen F.T., Price J.L. Sources of presumptive glutamatergic/aspartergic afferents to the rat ventral striatopallidal region. J. Comp. Neurol. 258:1987;317-338.
13. Greene J.R.T., Mason A. Effects of somatostatin and related peptides on the membrane potential and input resistance of rat ventral subicular neurons, in vitro. J. Pharmacol. Exp. Ther. 276:1996;426-432.
14. Groenewegen H.J., Vermeulen-Van Der Zee E., Kortschot A., Witter M.P. Organization of the projections from the subiculum to the ventral striatum in the rat. A study using anterograde transport of Phaseolus Vulgaris leucoagglutinin. Neuroscience. 23:1987;103-120.
15. Hersch S., Gutekunst C.-A., Rees H.D., Heilman C.J., Levey A.I. Distribution of m1-m4 muscarinic receptor proteins in the rat striatum: light and electron microscopic immunocytochemistry using subtype-specific antibodies. J. Neurosci. 14:1994;3351-3363.
16. Kawasaki H., Palmieri C., Avoli M. Muscarinic receptor activation induces depolarising potentials in bursting neurons of the rat subiculum. J. Neurophysiol. 82:1999;2590-2601.
17. Kelley A.E., Domesick V.B. The distribution of the projection from the hippocampal formation to the nucleus accumbens in the rat: an anterograde- and retrograde-horseradish peroxidase study. Neuroscience. 7:1982;2321-2335.
18. Kelley A.E., Domesick V.B., Nuta W.J.H. The amygdalostriatal projection in the rat-an anatomical study by anterograde and retrograde tracing methods. Neuroscience. 7:1982;615-630.
19. Legault M., Wise R.A. Injections of N-methyl-D-aspartate into the ventral hippocampus increase extracellular dopamine in the ventral tegmental area and nucleus accumbens. Synapse. 31:1999;241-249.
20. Legault M., Rompré P.-P., Wise R.A. Chemical stimulation of the ventral hippocampus elevates nucleus accumbens dopamine by activating dopaminergic neurons of the ventral tegmental area. J. Neurosci. 20:2000;1635-1642.
21. Leonard S., Breese C., Adams C., Benhammou K., Gault J., Stevens K., Lee M., Adler L., Olincy A., Ross R., Freedman R. Smoking and schizophrenia: abnormal nicotinic receptor expression. Eur. J. Pharmacol. 393:2000;237-242.
22. Louilot A., Le Moal M. Lateralized interdependence between limbicotemporal and ventrostriatal dopaminergic transmission. Neuroscience. 59:1994;495-500.
23. Marchi M., Sanguineti P., Raiteri M. Muscarinic receptors mediate direct inhibition of GABA release from rat striatal nerve terminals. Neurosci. Lett. 116:1990;347-351.
24. Mitchell S.N., Sharott A., Cooper J., Greenslade R.G. Ventral subiculum administration of the somatostatin receptor agonist MK-678 increases dopamine levels in the nucleus accumbens. Eur. J. Pharmacol. 395:2000;43-46.
25. Mitchell S.N., Yee B.K., Feldon J., Gray J.A., Rawlins J.N.P. Activation of the retrohippocampal region in the rat causes dopamine release in the nucleus accumbens: disruption by fornix section. Eur. J. Pharmacol. 407:2000;131-138.
26. Mogenson G.J., Nielsen M. A study of the contribution of hippocampal-accumbens-subpallidal projections to locomotor activity. Behav. Neural Biol. 42:1984;38-51.
27. Mullen G., Napier J., Balestra M., DeCory T., Hale G., Macor J., Mack R., Loch J. III, Wu E., Kover A., Verhoest P., Sampognaro A., Phillips E., Zhu Y., Murray R., Griffith R., Blosser J., Gurley D., Machulski A., Zongrone J., Rosen A., Gordon J. (-)-Spiro[1-azabicyclo[2.2.2]octane-3,5′-oxazolidin-2′-one], a conformationally restricted analogue of acetylcholine, is a highly selective full agonist at the α7 nicotinic acetylcholine receptor. J. Med. Chem. 43:2000;4045-4050.
28. Paxinos G., Watson C. The Rat Brain in Stereotaxic Coordinates. 4th ed. 1998;Academic Press, Sydney.
29. Rouse S.T., Marino M.J., Potter L.T., Conn P.J., Levey A.I. Muscarinic receptor subtypes involved in hippocampal circuits. Life Sci. 64:1999;501-509.
30. Santiago M.P., Potter L.T. Biotinylated m4-toxin demonstrates more M4 muscarinic receptor protein on direct than indirect striatal projection neurons. Brain Res. 894:2001;12-20.
31. 1 selective agonists. Synthesis and structure-activity relationships of 3-(1,2,5-thiadiazolyl)-1,2,5,6-tetrahydro-1-methylpyridines. J. Med. Chem. 35:1992;2274-2283.
32. Sauerberg P., Jeppesen L., Olesen P.H., Rasmussen T., Swerdberg M.D.B., Sheardown M.J., Fink-Jensen A., Thomsen C., Thogersen H., Rimvall K., Ward J.S., Calligaro D.O., DeLapp N.W., Bymaster F.P., Shannon H.E. Muscarinic agonists with antipsychotic-like activity: structure-activity relationships of 1,2,5-thiadiazole analogues with functional dopamine antagonist activity. J. Med. Chem. 41:1998;4378-4384.
33. Sesack S.R., Pickel V.M. Prefrontal cortical efferents in the rat synapse on unlabelled neuronal targets of catecholamine terminals in the nucleus accumbens septi and on dopamine neurons in the ventral tegmental area. Brain Res. 506:1990;166-168.
34. Sesack S.R., Pickel V.M. In the rat nucleus accumbens, hippocampal and catecholaminergic terminals converge on spiny neurons and are in opposition to each other. Brain Res. 527:1990;266-279.
35. 1 receptors. J. Pharmacol. Exp. Ther. 269:1994;271-281.
36. Shannon H.E., Bymaster F.P., Calligaro D.O., DeLapp N.W., Jones C., Perry K., Rasmussen K., Ward J.S., Fink-Jensen A., Sheardown M., Jeppesen L., Sauerberg P. Antipsychotic-like pharmacologic profile of the muscarinic agonist BuTAC. Schizophr. Res. 36:1999;314.
37. Sugita S., Uchimura N., Jiang Z.G., North R.A. Distinct muscarinic receptors inhibit release of gamma-aminobutyric acid and excitatory amino acids in mammalian brain. Proc. Natl. Acad. Sci. USA. 88:1991;2608-2611.
38. 1 receptors. Psychopharmacology. 151:2000;242-251.
39. Totterdell S., Smith A.D. Convergence of hippocampal and dopaminergic input onto identified neurons in the nucleus accumbens of the rat. J. Chem. Neuroanat. 2:1989;285-298.
40. Wu M., Brudzynski S.M. Mesolimbic dopamine terminals and locomotor activity induced from the subiculum. NeuroReport. 6:1995;1601-1604.
41. 2 receptors in the nucleus accumbens: an electrophysiological and behavioural study. Neuroscience. 23:1987;1041-1055.
42. Zhang W., Basile A.S., Gomeza J., Volpicelli L.A., Levey A.I., Wess J. Characterisation of central inhibitory muscarinic autoreceptors by the use of muscarinic acetylcholine receptor knock-out mice. J. Neurosci. 22:2002;1709-1717.